The improved efficacy of a biologic drug in combination with a conventional treatment in rheumatoid arthritis (RA) has been well demonstrated, but some biologic-naive patients are unable to tolerate drugs such as methotrexate. Limited data are available about which biologic to select for monotherapy in such patients, however.
The improved efficacy of a biologic drug in combination with a conventional treatment in rheumatoid arthritis (RA) has been well demonstrated, but some biologic-naive patients are unable to tolerate drugs such as methotrexate. Limited data are available about which biologic to select for monotherapy in such patients, however.
A recently published analysis, appearing in BMJ Open, used data from the Administrative Healthcare Database of Italy’s Lombardy region, as part of the RECord-linkage On Rheumatic Diseases (RECORD) study, to comparatively evaluate the persistence of treatment on different biologics used in monotherapy compared with combination therapy.
Click to read more about monotherapy for rheumatoid arthritis.
Patients with RA in the RECORD study were assessed to identify 799 patients who had at least 1 delivery of a first-line biologic as monotherapy, and 3679 patients who received combination therapy in the first line. Biologics used included abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, and tocilizumab. Rituximab was excluded due to local limitations on use. Monotherapy was associated with longer disease duration, hepatic and renal disease, heart failure, lower use of steroids, and lower use of nonsteroidal anti-inflammatory drugs.
Combination therapy has been shown in many studies to be associated with a 21% lower risk of drug failure, but among those who received monotherapy, considering etanercept as a reference point, the adjusted hazard ratio [HR] for biologic failure was 1.28 for adalimumab (95% CI, 1.03-1.59) and 2.41 for infliximab (95% CI, 1.85-3.15). Abatacept was associated with a reduced through not statistically significant risk of failure, and tocilizumab was approximately equal with etanercept. Among combination therapies, only infliximab was statistically inferior to etanercept monotherapy.
The authors of the analysis write that, while monotherapy is commonly observed, it is important to better understand the factors that drive monotherapy, such as comorbidities, body mass index, and higher disease activity.
The authors conclude that using biologics with conventional therapy is preferable to monotherapy, and further state that etanercept monotherapy should be preferred to infliximab and adalimumab when first-line monotherapy is necessary.
Reference
Silvagni E, Bortoluzzi A, Carrara G. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases. BMJ Open.2018;8(9):e021447. doi: 10.1136/bmjopen-2017-021447.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.